Executive summary

This study reported outcomes of 19 patients of B/P-RMS treated with PBT. With a median follow-up of 66.2 months, 5-year overall survival (OS) and progression-free survival (PFS) were 76%. Four patients (21%) experienced disease relapse, all presenting with local failure. The 5-year local control (LC) rate was 76%. Acute grade 2 toxicity was observed in two patients (11%, transient proctitis).

Late grade 2+ toxicity was observed in three patients (16%; n = 1 grade 2 skeletal deformity; n = 3 transient grade 2 urinary incontinence; one patient experienced both). This study concluded that PBT for B/P-RMS offers promising disease-related outcomes with an acceptable toxicity profile.

Key content topics